Amedisys — Investor Presentation (March 2017)
21 slides from Amedisys's investor presentation, Mar 21, 2017
Slide 1: Amedisys Investor Presentation March 2017
Amedisys Investor Presentation March 2017
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and u
Slide 3: Our National Reach: Amedisys Overview
Our National Reach Amedisys Overview Home Health Care Centers (327 locations) Hospice Care Centers (79 locations) Personal Care (14 locations) Highly Fragmented Industry $38,654 $17,399 $11,695 $6,300 $5,301 Medicare Exp per case Distribution and Cost by PAC Setting $1.4 B Revenue $110 M Adjusted EB
Slide 4: Post 1Q'17, HCHB disruption should no longer impact operations
Post 1Q’17, HCHB disruption should no longer impact operations HCHB 2.0 training will focus on optimization of the platform aimed at driving improved clinical outcomes and additional margin improvement Work on HCHB back office scale opportunities Home Health: Coming out of 2016 HCHB implementation,
Slide 5: Highlights and Summary Financial Results (Adjusted) – 4Q and Year End 2016
Highlights and Summary Financial Results (Adjusted) – 4Q 2016 and Year End 2016 (1) Amedisys Consolidated Revenue Growth: +8% EBITDA: $31M EBITDA Margin: 8.4% EPS: $0.44 Amedisys Highlights Same Store Admissions: Medicare FFS: +2% Total Episodic: +4% Non-Episodic: (9%) Other Statistics: Medicare rec
Slide 6: Amedisys Strategy: Four Areas of Focus
Amedisys Strategy: Four Areas of Focus Updated 4Q 2016 Clinicians Patient Health Clinicians Patient Health Outstanding Outcomes for Our Patients In Their Homes Amedisys Care Centers & Clinical Teams Current: HCHB implementation complete (disruption roll off by 2/28) Tracking towards full achievement
Slide 7: How We're Tracking
How We’re Tracking Clinical Distinction Employer of Choice Operational Excellence & Efficiency Driving Growth Outstanding Outcomes for Our Patients In Their Homes Care Centers & Clinical Teams Status Category Update Ongoing Initiative STARS Amedisys achieves a 4-Star average in the April 2017 HHC re
Slide 8: Clinical Distinction: Improvements in Stars
Clinical Distinction: Improvements in Stars Value Based Purchasing QPC Star Average PS Star Average Amedisys VBP State Avg 4.03 3.67 Large Cohort VBP Comp Avg1 3.53 3.54 Performance in VBP States Relative to Industry Internal analysis suggests that we will be a net receiver of funds in 2018 Metric O
Slide 9: Becoming Employer of Choice: Improving Return on Human Capital
Becoming Employer of Choice: Improving Return on Human Capital Total voluntary turnover continues to decline, achieving year end 2016 goal of 22.0% Full-time clinician turnover (who are accountable for 83% of total visits) has dropped to 18% Implementing proprietary productivity tool to maximize vis
Slide 10: Operational Excellence: Roadmap to EBITDA Improvement
$46M in annualized savings identified - increased visibility into efficiency initiatives Efficiencies and Disruption ($M) Operational Excellence: Roadmap to EBITDA Improvement All patients officially on HCHB Jan. 1. Disruption costs have been deeper than originally estimated but contained and return
Slide 11: Cost per Visit Components and Mitigation Plan
$83.46 $79.24 Components 4Q’15 4Q’16 Variance Detail Mitigation Plan Salaries $60.41 $62.94 $2.53 $1.93 driven by salary increases $0.14 HCHB disruption due to Admin/OT $0.46 clinician mix Expect normal levels post HCHB. Will reduce disruption recedes Initiative focused on optimizing clinician mix (
Slide 12: Driving Top Line Growth: Positive Metrics Across Business Segments
Driving Top Line Growth: Positive Metrics Across Business Segments We continue to grow across all lines of business 234 Opportunities Prospected 45 Opportunities Under Review 13 Active Processes * Includes 3,792 (Q1), 3,958 (Q2) 3,608 (Q3), and 3,569 (Q4) completed episodes from Infinity acquisition
Slide 13: Tenet Home Health and Hospice Asset Acquisition
Strategic acquisition of Tenet’s home health and hospice assets provides us with opportunity to prove out our clinical distinction with a large, national health system, and expand our service areas to cover more of their 450+ facilities (Hospitals and Surgery Centers) Tenet Home Health and Hospice A
Slide 14: Massachusetts: Integrated Post-Acute Home Care Model
We have expanded our Personal Care segment state wide in Massachusetts overlapping with our strong Home Health and Hospice operations. With the acquisition of Home Staff from Fallon Health in February 2017, we now have a strategic partner that we can pilot with to expand the types of patients we see
Slide 15: Management Team
Management Team Post HCHB implementation, our team has evolved adding bench strength in execution and operations, and deep Home Health and Hospice experience New Management Adds Retiring in April Chris Gerard COO Start Date: Jan 2017 20+ years of home health and hospice experience Formerly VP of Sou
Slide 16: Home Health and Hospice Segment (Adjusted) – 4Q 2016 and Year End 2016
Home Health and Hospice Segment (Adjusted) – 4Q 2016 and Year End 2016 (1) Medicare same store admissions growth positive for 4Q16 (+2%); revenue mix holding steady (76% Medicare FFS) Non-Medicare per visit admissions declined 9% during 4Q16 compared to prior year CPV increase anticipated due to pla
Slide 17: General & Administrative Expenses – Adjusted
General & Administrative Expenses – Adjusted (1,2) Highlights Year over year total G&A as a percentage of revenue decreased 150 basis points despite inclusion of roughly $8M related to acquisitions Home health segment G&A: 10 bps y/y increase as % of revenue; mainly driven acquired G&A from Infinity
Slide 18: CMS Update: Home Health and Hospice Reimbursement
CMS Update: Home Health and Hospice Reimbursement Home Health Medicare Reimbursement FY16 FY17 Final Market basket update 2.3% 2.8% Productivity adjustment (0.4%) (0.3%) Rebasing (2.4%) (2.3%) Nominal case-mix adjustment (0.9%) (0.9%) Net impact – Industry (1.4%) (0.7%) Case mix reweighting / Other
Slide 19: Debt and Liquidity Metrics
Debt and Liquidity Metrics Net debt defined as total debt outstanding ($96M) less cash balance ($30M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($110M). Liquidity defined as the sum of cash balance and available revolving line of credit. Despite deplo
Slide 20: Adjusted EBITDA to Free Cash Flow Reconciliation
Adjusted EBITDA to Free Cash Flow Reconciliation (1,2) The financial results for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016, and December 31, 2016 and year ended December 31, 2016 are adjusted for certain items and should be considered a non-GAAP financial measur
Slide 21: Income Statement Adjustments
Income Statement Adjustments (1) The financial results for the three-month periods ended March 31, 2016, June 30, 2016, September 30, 2016, December 31, 2016, and year-ended December 31, 2016 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of th